Regula Hits NIST Test: The Only Vendor Recognized Among Top Performers in All Critical Age Estimation Scenarios
9.9.2025 14:30:00 CEST | Business Wire | Press Release
For the first time, Regula, a global developer of identity verification (IDV) solutions and forensic devices, has taken part in the National Institute of Standards and Technology (NIST) evaluation for age estimation. This debut could hardly be stronger: Regula achieved the best result in the test, outperforming other vendors. Crucially, Regula’s technology demonstrated consistent accuracy across a wide range of demographics, making it the most universal solution on the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909879354/en/
Regula’s technology estimates age with unmatched precision, gaining top results in the independent NIST test
In addition, Regula ranked among the top three in two of the most critical age assurance scenarios: Challenge 25 and Child Online Safety (ages 13–16).
NIST is a globally respected authority in technology testing and standardization. Its Face Analysis Technology Evaluation (FATE) Age Estimation and Verification benchmark is an open, ongoing program that evaluates how software algorithms estimate age from facial photos. This capability is increasingly important nowadays, as regulators worldwide require reliable age checks to protect minors, enforce access restrictions, and confirm an individual’s age in the absence of official documents.
In this evaluation, NIST confirmed that Regula’s technology estimates age with exceptional accuracy across demographies, consistently outperforming other tested solutions. It came closer to the true age than any other solution tested so far. Regula’s algorithm delivered top results worldwide, with consistent leading accuracy across Europe, East Africa, and East and South Asia.
Beyond overall precision, Regula also excelled in age-restricted scenarios that are directly relevant to regulators and businesses. The Challenge 25 benchmark measures whether individuals who are close to 17 are reliably flagged for additional checks to prevent underage sales. The Child Online Safety benchmark focuses on accurately detecting users aged 13–16 in online environments, while minimizing misclassifications of younger children or adults. Achieving a top-three rank in both scenarios demonstrates that Regula’s technology not only excels in estimating real age but also in protecting minors and helping organizations comply with some of the toughest age-assurance requirements.
The age assurance enhancement will be included in the upcoming Regula Face SDK update. Designed for robust biometric verification, this solution enables thorough facial recognition and comparison, liveness detection, and age verification—an indispensable set of checks to prove that an individual is legitimate and real.
“Reaching the highest accuracy in the NIST evaluation proves the strength of our forensic-driven approach and biometric verification expertise. Just as important, the results confirm that Regula performs consistently across a wide range of real-world conditions, making our solution the most universal on the market. And we’re not stopping here: we are already working to make the technology even more precise and inclusive. Incorporating it into Regula Face SDK will equip our customers with a powerful, reliable way to estimate age in the most challenging environments," says Ihar Kliashchou, Chief Technology Officer at Regula.
Earlier this year, Regula was also recognized as a pioneer in online biometric age assurance for its comprehensive approach that combines advanced document verification with biometric authentication.
For more details on the NIST evaluation of age estimation technologies, see the official report. To learn what challenges and capabilities form today’s age verification solutions, please visit Regula’s website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909879354/en/
Contacts
Kristina – ks@regula.us
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom